| http://www.w3.org/ns/prov#value | - As Schloendorn writes in O'Reilly's new biotech journal Biocoder, the move is a response to the extremely high cost of operating in biotech today, where materials that cost effectively nothing to reproduce are stratospherically priced and locked in with license agreements that prohibit researchers from resupplying themselves.
|
